Meloxicam for oral administration
View Patent ↗The invention relates in its first aspect to a rapidly decomposing tablet for pain therapy containing meloxicam [4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide] in the form of a salt with an inorganic or organic base providing rapid absorption of the active substance, the process of its preparation by direct tabletting, and furthermore relates in a second aspect to the crystalline meloxicam meglumin salt mono- and dihydrate and the preparation thereof.
1. Crystalline meloxicam meglumin salt monohydrate or crystalline meloxicam meglumin salt dihydrate.
2. A process for preparing crystalline meloxicam-meglumin salt monohydrate, the process comprising:
(a) heating meloxicam and meglumin in a solvent mixture of a water-miscible organic solvent and water; and
(b) adding meloxicam-meglumin salt monohydrate seed crystals to the solvent mixture containing meloxicam and meglumin to obtain crystalline meloxicam-meglumin salt monohydrate.
3. The process of claim 2 , wherein the water-miscible organic solvent is acetone, methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, or dioxane.
4. The process of claim 2 , wherein the water-miscible organic solvent is acetone or ethanol.
5. The process of claim 2 , wherein the mixture of organic solvent and water are used in a ratio by volume of 10:1 to 100:1.
6. The process of claim 2 , wherein the meloxicam and meglumin are used in a molar ratio of 1:1.5 to 1.5:1.
7. The process of claim 2 , wherein a mixture of:
(A) 12.5 kg meloxicam; and
(B) 5 to 50 g of meloxicam-meglumin salt monohydrate seed crystals are added.
8. A process for preparing crystalline meloxicam-meglumin salt dihydrate, wherein crystalline meloxicam-meglumin salt monohydrate is treated at a relative humidity of at least 75%.
9. A process for preparing an orally administrable solid pharmaceutical preparation containing meloxicam in the form of the crystalline meloxicam-meglumin salt monohydrate, the process comprising:
(a) heating meloxicam and meglumin in a solvent mixture of a water-miscible organic solvent and water;
(b) adding meloxicam-meglumin salt monohydrate seed crystals to the solvent mixture containing meloxicam and meglumin to obtain crystalline meloxicam-meglumin salt monohydrate;
(c) separating crystalline meloxicam-meglumin salt monohydrate from the solvent mixture;
(d) optionally powdering the crystalline meloxicam-meglumin salt monohydrate and intimately mixing the crystalline meloxicam-meglumin salt monohydrate with a conventional powdered excipient or carrier to obtain a pharmaceutical mixture; and
(e) compressing the pharmaceutical mixture from step (d) directly into tablets with no granulation of the powder.
10. A process for preparing an orally administrable solid pharmaceutical preparation containing meloxicam in the form of the meloxicam-meglumin salt dihydrate, wherein crystalline meloxicam-meglumin salt monohydrate is treated at a relative humidity of at least 75%, the meloxicam-meglumin salt dihydrate thus obtained is optionally powdered, and then intimately mixed with suitable powdered excipient carrier and compressed directly into tablets without granulation of the powder.
11. A solid pharmaceutical composition for oral administration comprising meloxicam in the form of the crystalline meloxicam meglumin salt monohydrate.
12. A solid pharmaceutical composition for oral administration comprising meloxicam in the form of the crystalline meloxicam meglumin salt dihydrate.
13. The process of claim 2 , wherein a mixture of:
(A) meloxicam; and
(B) meloxicam-meglumin salt monohydrate seed crystals are added in a corresponding ratio by weight of A:B of 125:0.05-0.5.
14. The process of claim 2 , further comprising:
(c) separating crystalline meloxicam-meglumin salt monohydrate from the solvent mixture.
15. The composition in accordance with claim 11 , further comprising a conventional powered carrier or excipient.
16. The composition in accordance with claim 12 , further comprising a conventional powered carrier or excipient.
17. A method for the treatment of rheumatic diseases or acute pain, the method comprising orally administering a host suffering from rheumatic diseases or acute pain a therapeutic amount of composition in accordance with claim 11 .
18. A method for the treatment of rheumatic diseases or acute pain, the method comprising orally administering a host suffering rheumatic diseases or acute pain a therapeutic amount of composition in accordance with claim 12 .